Ljubica Glavaš-Obrovac

Prof. Ljubica Glavaš-Obrovac

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LKLuka Krstulović
Luka Krstulović
ISIvana Stolić
Ivana Stolić
MJMarijana Jukić
Marijana Jukić
TOTeuta Opačak-Bernardi
Teuta Opačak-Bernardi
KSKristina Starcevic
Kristina Starcevic
Ljubica Glavaš-ObrovacLjubica Glavaš-Obrovac
Ljubica Glavaš-Obrovac

24 March 2023 in Chemosensors
Verified
Journal Article
Open access
PDF file
SŠSilvija Šafranko
Silvija Šafranko
KJKristina Janđel
Kristina Janđel
MKMonika Kovačević
Monika Kovačević
Anamarija StankovićAnamarija Stanković
Anamarija Stanković
Maja Dutour SikirićMaja Dutour Sikirić
Maja Dutour Sikirić
Stela JokicStela Jokic
Stela Jokic
This work reports the preparation of amino acid-functionalized CQDs from citric acid by facile hydrothermal synthesis. The prepared N-doped CQDs exhibited excellent optical, physical, and chemical properties, and the differences were observed among the six different amino acids used as nitrogen dopants (Leu, Trp, Lys, Arg, Ala, His). Compared to the blank sample (without the addition of amino acids), N-doped CQDs have shown significantly higher quantum yield, also demonstrating the potential in metal ion sensing. The highest quantum yield of 36.45%, with a peak excitation/emission of 340/406 nm, was achieved using citric acid and amino acid Leu (CQD@Leu), treated at temperature of 180 °C during 9 h. The prepared samples were investigated toward metal ion selectivity (Ca2+, Cu2+, Fe3+, K+, Hg2+, Mg2+, Al3+, Mn2+, and Na+), and the CQD@Leu showed a selective and sensitive response upon the addition of Fe3+ ions. Therefore, CQD@Leu was selected for further investigation in Fe3+ detection in the model system and real well water samples. A developed model was described by a logistic function with a good coefficient of determination of R2 = 0.9982, while the linear range was determined in the concentration range from 0.3 mol dm−3 to 30 mol dm−3, with a determined limit of detection of LOD = 1.77 ± 0.01 mol dm−3 and limit of quantification of LOQ = 5.89 ± 0.04 mol dm−3. Furthermore, the results of the in vitro cytotoxicity test (MTT) with normal and tumor cell lines (MRC-5, HeLa, NCI-H358, and CaCo-2) clearly demonstrate the excellent biocompatibility of CQD@Leu.

6 October 2023 in Molecules
Verified
Journal Article
Open access
PDF file
LKLuka Krstulović
Luka Krstulović
KŠKatarina Mišković Špoljarić
Katarina Mišković Špoljarić
VRVesna Rastija
Vesna Rastija
Nikolina FilipovićNikolina Filipović
Nikolina Filipović
MBMiroslav Bajić
Miroslav Bajić
Ljubica Glavaš-ObrovacLjubica Glavaš-Obrovac
Ljubica Glavaš-Obrovac
The newly synthesized quinoline–benzimidazole hybrids containing two types of triazole-methyl-phenoxy linkers were characterized via NMR and elemental analysis. Additional derivatization was achieved by introducing bromine at the C-2 position of the phenoxy core. These novel hybrids were tested for their effects on the growth of the non-tumor cell line MRC-5 (human fetal lung fibroblasts), leukemia and lymphoma cell lines: Hut78, THP-1 and HL-60, and carcinoma cell lines: HeLa and CaCo-2. The results obtained, presented as the concentration that achieves 50% inhibition of cell growth (IC50 value), show that the compounds tested affect tumor cell growth differently depending on the cell line and the dose applied (IC50 ranged from 0.2 to >100 µM). The quinoline–benzimidazole hybrids tested, including 7-chloro-4-(4-{[4-(5-methoxy-1H-1,3-benzo[d]imidazol-2-yl)phenoxy]methyl}-1H-1,2,3-triazol-1-yl)quinoline 9c, 2-(3-bromo-4-{[1-(7-chloroquinolin-4-yl)-1H-1,2,3-triazol-4-yl]methoxy}phenyl)-N-propyl-1H-benzo[d]imidazol-5-carboximidamide trihydrochloride 10e, 2-{4-[(1-{2-[(7-chloroquinolin-4-yl)amino]ethyl}-1H-1,2,3-triazol-4-yl)methoxy]phenyl}-N-propyl-1H-benzo[d]imidazol-5-carboximidamide trihydrochloride 14e and 2-{3-bromo-4-[(1-{2-[(7-chloroquinolin-4-yl)amino]ethyl}-1H-1,2,3-triazol-4-yl)methoxy]phenyl}-N-propyl-1H-benzo[d]imidazol-5-carboximidamide trihydrochloride 15e, arrested the cell cycle of lymphoma (HuT78) cells. The calculated ADMET properties showed that the synthesized compounds violated at most two of Lipinski’s rules, making them potential drug candidates, but mainly for parenteral use due to low gastrointestinal absorption. The quinoline–benzimidazole hybrid 14e, which was shown to be a potent and selective inhibitor of lymphoma cell line growth, obtained the highest binding energy (−140.44 kcal/mol), by docking to the TAO2 kinase domain (PDB: 2GCD).

5 January 2023 in Molecules
Verified
Journal Article
Open access
PDF file
LKLuka Krstulović
Luka Krstulović
MLMarijana Leventić
Marijana Leventić
VRVesna Rastija
Vesna Rastija
KSKristina Starcevic
Kristina Starcevic
MJMaja Jirouš
Maja Jirouš
Ljubica Glavaš-ObrovacLjubica Glavaš-Obrovac
Ljubica Glavaš-Obrovac
In this study, new 7-chloro-4-aminoquinoline-benzimidazole compounds were synthesized and characterized by NMR, MS, and elemental analysis. These novel hybrids differ in the type of linker and in the substituent on the benzimidazole moiety. Their antiproliferative activities were evaluated on one non-tumor (MDCK1) and seven selected tumor (CaCo-2, MCF-7, CCRF-CEM, Hut78, THP-1, and Raji) cell lines by MTT test and flow cytometry analysis. The compounds with different types of linkers and an unsubstituted benzimidazole ring, 5d, 8d, and 12d, showed strong cytotoxic activity (the GI50 ranged from 0.4 to 8 µM) and effectively suppressed the cell cycle progression in the leukemia and lymphoma cells. After 24 h of treatment, compounds 5d and 12d induced the disruption of the mitochondrial membrane potential as well as apoptosis in HuT78 cells. The drug-like properties and bioavailability of the compounds were calculated using the Swiss ADME web tool, and a molecular docking study was performed on tyrosine-protein kinase c-Src (PDB: 3G6H). Compound 12d showed good solubility and permeability and bound to c-Src with an energy of −119.99 kcal/mol, forming hydrogen bonds with Glu310 and Asp404 in the active site and other residues with van der Waals interactions. The results suggest that compound 12d could be a leading compound in the further design of effective antitumor drugs.

20 September 2017 in New Journal of Chemistry
Verified
Journal Article
Closed access
PDF file
DSDijana Saftić
Dijana Saftić
MSMarijana Radić Stojković
Marijana Radić Stojković
BŽBiserka Žinić
Biserka Žinić
Ljubica Glavaš-ObrovacLjubica Glavaš-Obrovac
Ljubica Glavaš-Obrovac
MJMarijana Jukić
Marijana Jukić
Lidija-Marija TumirLidija-Marija Tumir
Lidija-Marija Tumir
A phenanthridine-triazolyluracilyl multifunctional ligand, linked by a lysine–glycine peptide, binds to poly rA–poly rU with micromolar affinity and selective fluorescence response.

24 May 2018 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
STStana Tokic
Stana Tokic
MŠMario Štefanić
Mario Štefanić
Ljubica Glavaš-ObrovacLjubica Glavaš-Obrovac
Ljubica Glavaš-Obrovac
AKAmit Kishore
Amit Kishore
ZNZdenka Navratilova
Zdenka Navratilova
MPMartin Petrek
Martin Petrek
Objective: Hashimoto’s thyroiditis (HT) is a common autoimmune thyroid disorder that frequently evolves from asymptomatic, T-cell mediated chronic inflammation toward overt hypothyroidism. Previously, we have demonstrated a role for T-bet, a T helper 1/CD8+ T cell transcription factor (TF), and FoxP3, a regulatory T cell TF, in disease progression and severity, but the basis behind their altered mRNA expression remains unknown. In this study, we aimed to leverage the role for microRNAs, representing negative transcriptional regulators, across the spectrum of HT clinical presentations using the same, well-characterized RNA sample cohort. Method: Ten hypothyroid, untreated patients (hypoHT), 10 hypothyroid cases rendered euthyroid by l-thyroxine therapy (substHT), 11 spontaneously euthyroid HT subjects (euHT), and 10 healthy controls (ctrl) were probed for three candidate immunoregulatory miRNA (miR-9-5p, miR-29a-3p, and miR-210-3p) using quantitative real-time PCR measurements. Data were normalized to U6snRNA and fold difference in expression calculated by the efficiency corrected 2−ΔΔCt model. Results: Compared to healthy controls, peripheral blood (PB) T cells of HT patients exhibited significantly diminished miR-29a-3p expression levels [median expression levels (IQR), HT vs CTRL, 0.62 (0.44–1.01) vs 1.373 (0.63–2.7), P = 0.046], and a similar, but not significant decline in miR-210-3p abundance [HT vs CTRL, 0.64 (0.39–1.31) vs 1.2 (0.5–2.56), P = 0.24, Wilcoxon test]. A significant inverse correlation was observed between the two differentially expressed transcripts, T-bet mRNA and miR-29a-3p. Moreover, altered miR-29a-3p/T-bet expression in T cells of untreated HT patients was related to low serum FT4, high serum thyrotropin, and decreased thyroid volumes. Of note, miR-210-3p expression was positively correlated to HIF1α, and inversely to FoxP3 mRNA levels, but no evidence of differential expression for any of these miRNA–mRNA pairs was observed. Finally, miR-9-5p expression levels were no different in HT vs control comparisons, or related to clinicopathological features. Conclusion: T cell miR-29a-3p is downregulated in HT patients and associated with clinical and biochemical parameters of progressive thyroid injury, plausibly subsequent to altered control of T-bet expression in PB T cells. As such miR-29a-3p/T-bet axis should be further explored as a biomarker or as a plausible target for therapeutic interventions in HT.